BRPI0605893A - composição farmacêutica, cápsula única, forma unitária de dosagem oral única, processos de produção de uma composição farmacêutica, dos ingredientes ativos cristalinos e recristalizado do ácido suberoilanilida hidroxámico, e de obtenção do ácido suberoilanilida hidroxámico cristalino, e, composição cristalina - Google Patents

composição farmacêutica, cápsula única, forma unitária de dosagem oral única, processos de produção de uma composição farmacêutica, dos ingredientes ativos cristalinos e recristalizado do ácido suberoilanilida hidroxámico, e de obtenção do ácido suberoilanilida hidroxámico cristalino, e, composição cristalina

Info

Publication number
BRPI0605893A
BRPI0605893A BRPI0605893-0A BRPI0605893A BRPI0605893A BR PI0605893 A BRPI0605893 A BR PI0605893A BR PI0605893 A BRPI0605893 A BR PI0605893A BR PI0605893 A BRPI0605893 A BR PI0605893A
Authority
BR
Brazil
Prior art keywords
crystalline
pharmaceutical composition
hydroxamic
acid
composition
Prior art date
Application number
BRPI0605893-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Jeannie Chow Wong
Aaron S Cote
Erik A Dienemann
Kimberly Gallagher
Craig Ikeda
Justin Moser
Pavol Rajniak
Robert A Reed
Cindy Starbuck
Hsien-Hsin Tung
Qingxi Wang
Benjamin Max Cohen
Vincent R Capodanno
Brian Sell
Thomas A Miller
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0605893(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BRPI0605893A publication Critical patent/BRPI0605893A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI0605893-0A 2005-05-20 2006-05-16 composição farmacêutica, cápsula única, forma unitária de dosagem oral única, processos de produção de uma composição farmacêutica, dos ingredientes ativos cristalinos e recristalizado do ácido suberoilanilida hidroxámico, e de obtenção do ácido suberoilanilida hidroxámico cristalino, e, composição cristalina BRPI0605893A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68287505P 2005-05-20 2005-05-20
US69312805P 2005-06-23 2005-06-23
PCT/US2006/018737 WO2006127319A2 (en) 2005-05-20 2006-05-16 Formulations of suberoylanilide hydroxamic acid and methods for producing same

Publications (1)

Publication Number Publication Date
BRPI0605893A true BRPI0605893A (pt) 2007-12-18

Family

ID=37452585

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0605893-0A BRPI0605893A (pt) 2005-05-20 2006-05-16 composição farmacêutica, cápsula única, forma unitária de dosagem oral única, processos de produção de uma composição farmacêutica, dos ingredientes ativos cristalinos e recristalizado do ácido suberoilanilida hidroxámico, e de obtenção do ácido suberoilanilida hidroxámico cristalino, e, composição cristalina

Country Status (20)

Country Link
US (4) US8093295B2 (OSRAM)
EP (2) EP1853245A2 (OSRAM)
JP (2) JP5264174B2 (OSRAM)
KR (2) KR100884500B1 (OSRAM)
AR (1) AR055953A1 (OSRAM)
AU (3) AU2006249440C1 (OSRAM)
BR (1) BRPI0605893A (OSRAM)
CA (1) CA2580367C (OSRAM)
CR (1) CR8912A (OSRAM)
DO (1) DOP2006000113A (OSRAM)
EC (1) ECSP077263A (OSRAM)
IL (1) IL181070A0 (OSRAM)
MA (1) MA28804B1 (OSRAM)
MX (1) MX2007002047A (OSRAM)
MY (1) MY144613A (OSRAM)
NI (1) NI200700031A (OSRAM)
NZ (2) NZ553204A (OSRAM)
PE (1) PE20061390A1 (OSRAM)
TW (2) TWI415603B (OSRAM)
WO (2) WO2006127321A2 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI415603B (zh) * 2005-05-20 2013-11-21 Merck Sharp & Dohme １，８－辛二醯基苯胺羥胺酸（ｓｕｂｅｒｏｙｌａｎｉｌｉｄｅ ｈｙｄｒｏｘａｍｉｃ ａｃｉｄ）之調配物及其製配方法
AU2009305214B2 (en) 2008-10-15 2015-06-25 Generics [Uk] Limited Process for the preparation of vorinostat
NZ593585A (en) * 2008-11-26 2012-12-21 Generics Uk Ltd Crystalline forms of vorinostat (suberoylanilide hydroxamic acid)
EP2362870A2 (en) * 2008-11-26 2011-09-07 Generics [UK] Limited Novel processes and pure polymorphs
US20110313044A1 (en) * 2010-06-18 2011-12-22 Urquima S.A. Polymorphs of Suberoylanilide Hydroxamic Acid
WO2018011811A2 (en) * 2016-07-13 2018-01-18 Rappaport Family Institute For Research In The Medical Sciences Inhibitors of cytoplasmic histone deacetylase 4 complex for treating or preventing vascular or valve calcification
CN107362148B (zh) * 2017-07-27 2020-04-21 东曜药业有限公司 一种治疗肿瘤的药物组合物及其制备方法和应用
EP4007585A4 (en) 2019-08-02 2023-11-08 OneHealthCompany, Inc. TREATMENT OF CANINE CANCERS

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
US5608108A (en) * 1988-11-14 1997-03-04 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5055608A (en) * 1988-11-14 1991-10-08 Sloan-Kettering Institute For Cancer Research Novel potent inducers of thermal differentiation and method of use thereof
US5175191A (en) * 1988-11-14 1992-12-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
USRE38506E1 (en) * 1991-10-04 2004-04-20 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5369108A (en) * 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5700811A (en) 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5635532A (en) * 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
JP3170069B2 (ja) * 1992-10-06 2001-05-28 日水製薬株式会社 徐放性顆粒剤
US6030961A (en) 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
US6043389A (en) * 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
US6124495A (en) 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
US6262116B1 (en) * 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
IL142531A0 (en) 1998-10-13 2002-03-10 Fujisawa Pharmaceutical Co Cyclic peptide compound, processes for the preparation thereof and pharmaceutical compositions containing the same
JP2003500052A (ja) 1999-05-03 2003-01-07 メチルジーン インコーポレイテッド ヒストン脱アセチル酵素の抑制
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
TR200201052T2 (tr) 1999-09-08 2003-01-21 Sloan-Kettering Institute For Cancer Research Yeni hücre farklılaştırıcı ajanlar sınıfı ve hıstone deacetylase inhibitörleri, ve burada kullanım yöntemleri
DK1233958T3 (da) 1999-11-23 2011-10-17 Methylgene Inc Hæmmere af histondeacetylase
WO2001070675A2 (en) 2000-03-24 2001-09-27 Methylgene, Inc. Inhibitors of histone deacetylase
WO2002015921A2 (en) 2000-08-18 2002-02-28 The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
EP2292593A3 (en) 2000-09-29 2011-05-25 TopoTarget UK Limited Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
AU2002243231A1 (en) * 2000-11-21 2002-07-24 Wake Forest University Method of treating autoimmune diseases
AR035659A1 (es) 2000-12-07 2004-06-23 Hoffmann La Roche Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos
US6495719B2 (en) * 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
EP1532244A4 (en) * 2001-06-14 2005-12-14 Bristol Myers Squibb Co NEW HISTONIC HUMAN DEACETYLASES
EP2269609A3 (en) * 2001-10-16 2012-07-11 Sloan-Kettering Institute for Cancer Research Treatment of neurodegenerative diseases and cancer of the brain with SAHA
US20040132643A1 (en) * 2002-01-09 2004-07-08 Fojo Antonio Tito Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms
WO2003070188A2 (en) * 2002-02-15 2003-08-28 Sloan-Kettering Institute For Cancer Research Method of treating trx mediated diseases
MXPA04008577A (es) * 2002-03-04 2005-07-13 Aton Pharma Inc Metodos para inducir diferenciacion terminal.
US20060276547A1 (en) * 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US7456219B2 (en) * 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
AU2003226408B2 (en) * 2002-04-15 2007-06-14 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
DE10218106A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Arzneimittelwirkstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
EP1567142A4 (en) * 2002-11-20 2005-12-14 Errant Gene Therapeutics Llc TREATMENT OF PULMONARY CELLS WITH HISTONE DEACETYLASE INHIBITORS
CA2520611A1 (en) * 2003-04-01 2004-10-21 Memorial Sloan-Kettering Cancer Center Hydroxamic acid compounds and methods of use thereof
PL379887A1 (pl) * 2003-08-26 2006-11-27 Merck Hdac Research, Llc Sposób leczenia raka inhibitorami HDAC
TWI415603B (zh) * 2005-05-20 2013-11-21 Merck Sharp & Dohme １，８－辛二醯基苯胺羥胺酸（ｓｕｂｅｒｏｙｌａｎｉｌｉｄｅ ｈｙｄｒｏｘａｍｉｃ ａｃｉｄ）之調配物及其製配方法
EP1933825A2 (en) 2005-08-18 2008-06-25 Merck and Co., Inc. Combination methods of saha and targretin for treating cancer
US20070117815A1 (en) 2005-11-04 2007-05-24 James Pluda Method of treating cancers with SAHA and pemetrexed
WO2007056162A2 (en) 2005-11-04 2007-05-18 Merck & Co., Inc. Methods of treating cancers with saha, carboplatin, and paclitaxel and other combination therapies
US20070197568A1 (en) * 2005-11-04 2007-08-23 Paul Bunn Methods of using SAHA and Erlotinib for treating cancer

Also Published As

Publication number Publication date
ECSP077263A (OSRAM) 2007-04-26
CA2580367A1 (en) 2006-11-30
DOP2006000113A (es) 2006-10-31
MY144613A (en) 2011-10-04
NZ594669A (en) 2013-02-22
EP1853245A2 (en) 2007-11-14
JP2011251985A (ja) 2011-12-15
AR055953A1 (es) 2007-09-12
NI200700031A (es) 2008-03-03
US20100119596A1 (en) 2010-05-13
US20080132575A1 (en) 2008-06-05
KR100993135B1 (ko) 2010-11-10
CR8912A (es) 2008-02-21
TWI365068B (en) 2012-06-01
US8288440B2 (en) 2012-10-16
EP2292221A3 (en) 2011-08-10
MA28804B1 (fr) 2007-08-01
WO2006127319A3 (en) 2007-03-29
US8093295B2 (en) 2012-01-10
TW200727892A (en) 2007-08-01
TWI415603B (zh) 2013-11-21
KR20080113135A (ko) 2008-12-26
WO2006127319A2 (en) 2006-11-30
AU2010201359A1 (en) 2010-04-29
US20100112046A1 (en) 2010-05-06
AU2009201650A1 (en) 2009-05-21
AU2009201652A1 (en) 2009-05-21
PE20061390A1 (es) 2007-01-15
WO2006127321A3 (en) 2007-03-22
JP2008519081A (ja) 2008-06-05
NZ553204A (en) 2011-09-30
JP5264174B2 (ja) 2013-08-14
TW201034660A (en) 2010-10-01
AU2009201650B2 (en) 2011-09-15
KR20070062505A (ko) 2007-06-15
AU2009201652B2 (en) 2011-10-06
US8450372B2 (en) 2013-05-28
JP5308486B2 (ja) 2013-10-09
AU2006249440B2 (en) 2009-03-12
CA2580367C (en) 2012-08-21
US20100113829A1 (en) 2010-05-06
IL181070A0 (en) 2007-07-04
EP2292221A2 (en) 2011-03-09
MX2007002047A (es) 2007-04-12
AU2006249440C1 (en) 2009-08-13
WO2006127321A2 (en) 2006-11-30
KR100884500B1 (ko) 2009-02-20
AU2006249440A1 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
ES2372421T3 (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopáusicos.
BR112012009376B8 (pt) composição farmacêutica sólida compreendendo um inibidor de sglt-2 e sua forma de dosagem farmacêutica
ECSP066914A (es) FORMA CRISTALINA dd DEL CLORHIDRATO DE LA IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN Y LAS COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN
MX2011012122A (es) Derivados de tiofeno.
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
MX2010011381A (es) Composiciones que comprenden farmacos levemente basicos y formas de dosificacion de liberacion controlada.
UY32599A (es) Formulación oral sólida de abt-263
EA201590449A1 (ru) Перорально вводимая лекарственная композиция
BRPI0600796B8 (pt) forma gama-cristalina de cloridrato de ivabradina, processo para preparação do mesmo e composições farmacêuticas contendo o mesmo
BR112012019374A2 (pt) composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo
SI3029039T1 (en) Pharmaceutical formulations containing crystalline forms of (R) -7-chloro-N- (quinuclidin-3-yl) benzo (b) thiophene-2-carboxamide hydrochloride monohydrate
BRPI0517662A (pt) partìculas de ramipril estabilizadas revestidas, processo para o revestimento de ramipril, composição farmacêutica oral sólida, métodos para evitar e tratar distúrbios cardiovasculares, e, processo para fabricar uma composição farmacêutica
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
BRPI0807285A2 (pt) "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto"
BR0314299A (pt) Derivados de pirrolidona como inibidores de mao-b
MA35455B1 (fr) (wo2013045407) dérivés d'estra-1,3,5(10),16-tétraène-3-carboxamide, procédé pour leur fabrication, préparations pharmaceutiques contenant ces substances ainsi que leur utilisation dans la fabrication de médicaments
MY156302A (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ß-AMYLOID DISEASES AND SYNUCLEINOPATHIES
WO2008120070A3 (en) 2(hydroxyethyl)trimethylammonium thioctate (choline thioctate) displaying hepatoprotective, hypoammoniemic and detoxic action, a method for its production and a pharmaceutical composition based thereon
BR112014014795A2 (pt) sistema de pélete de multiunidade de liberação imediata
JP2018521007A5 (OSRAM)
BRPI0605893A (pt) composição farmacêutica, cápsula única, forma unitária de dosagem oral única, processos de produção de uma composição farmacêutica, dos ingredientes ativos cristalinos e recristalizado do ácido suberoilanilida hidroxámico, e de obtenção do ácido suberoilanilida hidroxámico cristalino, e, composição cristalina
WO2007144083A3 (de) Ache-nmda-kombinationswafer
NO20070952L (no) Formuleringer av suberoylanilidhydroksaminsyre og fremgangsmate for fremstilling av slike
JP2018039810A5 (OSRAM)
BRPI0620229B8 (pt) formulações farmaceuticas e processos de produção da ditas formulações

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

Free format text: ALTERADO DE: MERCK AND CO., INC.

B25A Requested transfer of rights approved

Owner name: SCHERING CORPORATION, (US)

B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B25G Requested change of headquarter approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]